Arbutus Biopharma logo

Arbutus Biopharma

ABUS | NASDAQ
Chart Builder DCF Calculator
$4.04
-$0.05 (-1.22%)
At close: Nov 16, 2026, 4:00 PM ET
$4.17
+$0.13 (+3.22%)
After-hours: Nov 16, 2026, 7:33 PM ET
-1.22%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
81.4
Fundamentals Excellent
Market Sentiment Neutral
Moat Narrow
Sector Rank #15/1021 (Top 1%)

Key Statistics

Market Data

Market Cap $802.66M
1D Range
4.00 4.18
52W Range
3.66 5.22

Valuation (TTM)

PE 3.61
PB 9.36
EV/EBITDA 2.12

Valuation (NTM)

Forward PE 5.53
Forward PEG -0.01
Price Target $8.50
Loading financial charts...

Profile

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline compr...

Sector Healthcare
Industry Biotechnology
Employees 19
IPO Date Jul 26, 2007
Fiscal Year January - December

Latest News

Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share

3 months ago · globenewswire.com

Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share

Earnings

Latest Earnings
Nov 10, 2026
EPS
$0.3
Beat +1393.10%
REV
$299K
Miss -70.10%
Next Earnings
Mar 4, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.